Both Dentsply and Sirona released a joint statement on the merger, planning both shareholder meetings for the same day in their respective U.S. headquarters in York, Penn. and New York, N.Y., respectively.
The deal has already past both Denstply and Sirona’s boards, who voted unanimously for the merger of equals, according to an SEC filing from Dentsply.
Late last month, the companies announced that the merger cleared the U.S. Federal Trade Commission’s waiting period, clearing the way for a close in the 1st quarter of 2016.
The merger, announced in September, would create the world’s largest dental equipment maker. It calls for Sirona shareholders to receive 1.8142 XRAY shares for each SIRO share they own. At roughly $98.06 apiece, that’s about a 0.7% discount on Sirona’s $99.31 closing price the day before the deal was announced.
The combined company, Dentsply Sirona, is slated to trade on the NASDAQ exchange under the XRAY symbol. At that point Dentsply shareholders will own 58% of the new entity, with Sirona shareholders owning the rest. Dentsply Sirona’s global headquarters will be in York, Pa., with international HQ in Salzburg, Austria.
Sirona president & CEO Jeffrey Slovin was named CEO of the new dental giant, with Dentsply chairman & CEO Bret Wise as executive chairman. Dentsply president & CFO Christopher Clark was named president & COO, Technologies, with executive VP & COO James Mosch as president & COO of dental & healthcare consumables. Sirona’s CFO, Ulrich Michel, was tapped for executive vice president & CFO at Dentsply Sirona.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.